Table 5.
Teriparatide utilization and overall utilization and costs in the 12 month follow-up period
|
Measure |
PDC* < 50% |
PDC 50% ≤ 80% |
PDC ≥ 80% |
Persistent |
Non-persistent |
|---|---|---|---|---|---|
| (low adherent) | (moderately adherent) | (highly adherent) | (60 day gap) | ||
|
Total Patients |
541 |
57 |
163 |
181 |
580 |
|
Inpatient Hospitalizations |
|||||
| Members with Hospitalization n,(%) |
116 (21.4%) |
16 (28.1%) |
26 (16.%) |
31 (17.13%) |
127 (21.9%) |
| Hospitalizations Per Member** |
0.4 (± 0.9) |
0.5 (± 1.10) |
0.2 (± 0.6) |
0.3 (± 0.7) |
0.4 (± 0.9) |
| 0 [0 - 6] |
0 [0 - 5] |
0 [0 - 4] |
0 [0 - 4] |
0 [0 - 6] |
|
|
Emergency Room Visits |
|||||
| Members with Visit n,(%) Δ ¥ |
180 (33.27%) |
17 (29.82%) |
39 (23.93%) |
43 (23.76%) |
193 (33.28%) |
| Visits Per Member** |
0.7 (± 1.8) |
0.5 (± 0.8) |
0.4 (± 1.1) |
0.4 (± 1.04) |
0.7 (± 1.7) |
| 0 [0 - 30] |
0 [0 - 3] |
0 [0 - 9] |
0 [0 - 9] |
0 [0 - 30] |
|
|
Outpatient Visits |
|||||
| Members with Visit n,(%) |
540 (99.8%) |
57 (100.0%) |
163 (100.0%) |
181 (100.0%) |
579 (99.8%) |
| Visits Per Member** |
35.4 (± 34.2) |
39. (± 39.8) |
32.3 (± 28.6) |
32.7 (± 29.7) |
35.7 (± 34.6) |
| 26 [0 - 320] |
24 [1 - 192] |
23 [3 - 195] |
23 [3 - 195] |
26 [0 - 320] |
|
|
Pharmacy Claims |
|||||
| Members with Pharmacy Claim n,(%) |
541 (100.0%) |
57 (100.0%) |
163 (100.0%) |
181 (100.0%) |
580 (100.0%) |
| Pharmacy Claims Per Member** † ‡ |
44.36 (± 31.01) |
43.96 (± 28.70) |
52.12 (± 35.06) |
51.20 (± 34.72) |
44.37 (± 30.79) |
| 38 [1 - 214] |
37 [4 - 127] |
41 [6 - 186] |
40 [6 - 186] |
39 [1 - 214] |
|
| |
|||||
|
Total Healthcare Cost** † ‡ |
$15,528 (± $37,713) |
$25,574 (± $28,620) |
$21,033 (± $13,136) |
$21,046 (± $13,560) |
$16,341 (± $37,485) |
| $7,272 [$1,097 - $758,916] |
$15,124 [$6,403 - $172,809] |
$15,777 [$9,745 - $87,302] |
$15,777 [$7,901 - $87,302] |
$7,562 [$1,097 - $758,916] |
|
| |
|||||
| Inpatient Hospitalization Cost** |
$4,897 (± $26,941) |
$8,448 (± $21,125) |
$2,198 (± $7,342) |
$2,535 (± $7,961) |
$5,224 (± $26,775) |
| $0 [$0 - $562,430] |
$0 [$0 - $123,486] |
$0 [$0 - $57,410] |
$0 [$0 - $57,410] |
$0 [$0 - $562,430] |
|
| |
|||||
| Emergency Room Visit Cost** |
$465 (± $2,840) |
$330 (± $971) |
$211 (± $711) |
$205 (± $686) |
$461 (± $2,759) |
| $0 [$0 - $62,129] |
$0 [$0 - $5,486] |
$0 [$0 - $6,124] |
$0 [$0 - $6,124] |
$0 [$0 - $62,129] |
|
| |
|||||
| Outpatient Cost** |
$5,806 (± $8,860) |
$6,439 (± $8,880) |
$5,151 (± $6,428) |
$5,118 (± $6,290) |
$5,899 (± $8,950) |
| $2,689 [$0 - $91,816] |
$2,724 [$93 - $44,149] |
$2,740 [$0 - $34,442] |
$2,583 [$0 - $34,442] |
$2,771 [$0 - $91,816] |
|
| |
|||||
| Pharmacy Cost** † ‡ | $4,361 (± $5,344) |
$10,358 (± $5,657) |
$13,472 (± $3,787) |
$13,187 (± $3,935) |
$4,757 (± $5,597) |
| $3,445 [$829 - $72,703] | $8,915 [$5,902 - $40,300] | $12,301 [$9,130 - $34,737] | $12,080 [$5,839 - $34,737] | $3,567 [$829 - $72,703] |
* Proportion of days covered.
**Mean, standard deviation, median, [range].
† ANOVA pairwise comparison between PDC < 50% and PDC ≥ 80% groups, p < 0.05.
‡ t-test between ‘Persistent’ and ‘Non-Persistent’ (60 Day Gap) groups, p < 0.05.
Δ Chi-square comparison between PDC < 50% and PDC ≥ 80% groups, p < 0.05.
¥ Chi-square comparison between ‘Persistent’ and ‘Non-Persistent’ (60 Day Gap) groups, p < 0.05.